These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2952145)

  • 21. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.
    Kim B; Semelka RC; Ascher SM; Chalpin DB; Carroll PR; Hricak H
    Radiology; 1994 Oct; 193(1):239-45. PubMed ID: 8090898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CT of noncystic liver lesions: bolus enhancement.
    Marchal GJ; Baert AL; Wilms GE
    AJR Am J Roentgenol; 1980 Jul; 135(1):57-65. PubMed ID: 6249108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Determining the depth of infiltration in urinary bladder carcinoma with contrast medium enhanced dynamic magnetic resonance tomography. With reference to postoperative findings and inflammation].
    Venz S; Ilg J; Ebert T; Hierholzer J; Friedrichs R; Hosten N; Felix R
    Urologe A; 1996 Jul; 35(4):297-304. PubMed ID: 8928358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary bladder pseudolesions on contrast-enhanced helical CT: frequency and clinical implications.
    Olcott EW; Nino-Murcia M; Rhee JS
    AJR Am J Roentgenol; 1998 Nov; 171(5):1349-54. PubMed ID: 9798877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the pancreas after single bolus injection combined with spiral scanning. A comparative study with conventional incremental scanning after biphasic contrast injection.
    Rigauts H; Marchal G; Baert AL
    Rofo; 1992 May; 156(5):471-4. PubMed ID: 1596552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bolus geometry and dynamics after intravenous contrast medium injection.
    Claussen CD; Banzer D; Pfretzschner C; Kalender WA; Schörner W
    Radiology; 1984 Nov; 153(2):365-8. PubMed ID: 6484168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic CT enhancement. Part I. Alterations in the volume of contrast material within the same patients.
    Chambers TP; Baron RL; Lush RM
    Radiology; 1994 Nov; 193(2):513-7. PubMed ID: 7972770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical fat emulsion at computed tomography of bladder tumours.
    Ahlberg NE; Berlin T; Calissendorff B; Collste L; Gustavsson G; Wijkström H
    Acta Radiol Diagn (Stockh); 1981; 22(6):645-7. PubMed ID: 7347114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast media in body computed tomography: experimental and theoretical background background, present limitations, and proposals for improved diagnostic efficacy.
    Dean PB
    Invest Radiol; 1980; 15(6 Suppl):S164-9. PubMed ID: 7203918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Computed X-ray tomography in cases of metastatic brain tumors].
    Gołabek R; Touitou D; Wackenheim A
    Neurol Neurochir Pol; 1980; 14(1):1-13. PubMed ID: 7374888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Possibilities and limitations of computed tomographic staging of bladder carcinoma].
    Lorenz R; Beyer D; Allhoff E; Mödder U
    Rofo; 1984 Jun; 140(6):660-5. PubMed ID: 6429779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT.
    Verburg FA; Apitzsch J; Lensing C; Kuhl CK; Pietsch H; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Dec; 82(12):2348-52. PubMed ID: 24113432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pseudosarcomatous fibromyxoid tumor of the bladder: biphasic contrast-enhanced helical CT findings.
    Miki SC; Kwatra A; Kawashima A; Milam JD; Goldman SM; Sandler CM
    J Comput Assist Tomogr; 1997; 21(2):271-3. PubMed ID: 9071299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic helical CT: contrast material injection protocol.
    Foley WD; Hoffmann RG; Quiroz FA; Kahn CE; Perret RS
    Radiology; 1994 Aug; 192(2):367-71. PubMed ID: 8029399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peak contrast enhancement in CT and MR angiography: when does it occur and why? Pharmacokinetic study in a porcine model.
    Bae KT
    Radiology; 2003 Jun; 227(3):809-16. PubMed ID: 12702823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravascular enhancement with identical iodine delivery rate using different iodine contrast media in a circulation phantom.
    Mihl C; Wildberger JE; Jurencak T; Yanniello MJ; Nijssen EC; Kalafut JF; Nalbantov G; Mühlenbruch G; Behrendt FF; Das M
    Invest Radiol; 2013 Nov; 48(11):813-8. PubMed ID: 23857135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bladder tumor staging: comparison of conventional and gadolinium-enhanced dynamic MR imaging and CT.
    Tanimoto A; Yuasa Y; Imai Y; Izutsu M; Hiramatsu K; Tachibana M; Tazaki H
    Radiology; 1992 Dec; 185(3):741-7. PubMed ID: 1438756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of varying rates of low-osmolarity contrast media injection for hepatic CT: correlation with indocyanine green transit time.
    Harmon BH; Berland LL; Lee JY
    Radiology; 1992 Aug; 184(2):379-82. PubMed ID: 1620831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.